科伦药业：第三季度营收为41.93亿元

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the third quarter of 2025, indicating ongoing financial challenges and pressures on profitability [1] Financial Performance - The revenue for the third quarter was 4.193 billion yuan, representing a year-on-year decrease of 15.48% [1] - The net profit for the third quarter was 200 million yuan, down 70.18% year-on-year [1] - For the first three quarters, the total revenue was 13.277 billion yuan, reflecting a year-on-year decline of 20.92% [1] - The net profit for the first three quarters was 1.201 billion yuan, which is a decrease of 51.41% compared to the previous year [1] Contributing Factors - The decline in performance was primarily attributed to reduced product sales revenue and licensing income [1] - Additional pressures on profit margins were caused by decreased investment income from joint ventures and an increase in inventory impairment provisions [1]